NASDAQ:NEO NeoGenomics Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding NeoGenomics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $8.37 +0.22 (+2.70%) (As of 07/1/2022 12:00 AM ET) Add Compare Share Today's Range$8.11▼$8.5850-Day Range$7.06▼$11.2552-Week Range$6.85▼$54.74Volume2.88 million shsAverage Volume1.97 million shsMarket Capitalization$1.04 billionP/E RatioN/ADividend YieldN/APrice Target$20.82 ProfileAnalyst RatingsChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media NeoGenomics Stock Forecast (MarketRank)Analyst RatingModerate Buy2.70 Rating ScoreUpside/Downside148.7% Upside$20.82 Price TargetShort InterestBearish6.93% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.06Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.03) to ($0.79) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.1.76 out of 5 starsMedical Sector348th out of 1,429 stocksTesting Laboratories Industry1st out of 1 stocks 3.4 Analyst's Opinion Consensus RatingNeoGenomics has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on 7 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $20.82, NeoGenomics has a forecasted upside of 148.7% from its current price of $8.37.Amount of Analyst CoverageNeoGenomics has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.93% of the float of NeoGenomics has been sold short.Short Interest Ratio / Days to CoverNeoGenomics has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NeoGenomics has recently increased by 7.53%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldNeoGenomics does not currently pay a dividend.Dividend GrowthNeoGenomics does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NEO. Previous Next 1.7 News and Social Media Coverage News SentimentNeoGenomics has a news sentiment score of 0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for NeoGenomics this week, compared to 4 articles on an average week.Search InterestOnly 8 people have searched for NEO on MarketBeat in the last 30 days. This is a decrease of -56% compared to the previous 30 days.MarketBeat FollowsOnly 8 people have added NeoGenomics to their MarketBeat watchlist in the last 30 days. This is a decrease of -47% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NeoGenomics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.00% of the stock of NeoGenomics is held by insiders.Percentage Held by Institutions95.03% of the stock of NeoGenomics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for NeoGenomics are expected to grow in the coming year, from ($1.03) to ($0.79) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NeoGenomics is -26.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NeoGenomics is -26.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeoGenomics has a P/B Ratio of 0.93. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive NEO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeoGenomics and its competitors with MarketBeat's FREE daily newsletter. Email Address About NeoGenomics (NASDAQ:NEO)NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.Read More NEO Stock News HeadlinesJuly 2, 2022 | bloomberg.comAt 7.5% CAGR, Clinical Laboratory Test Market to hit USD 320.7 Billion in 2028, Says Brandessence Market Research - BloombergJune 30, 2022 | finance.yahoo.comAt 7.5% CAGR, Clinical Laboratory Test Market to hit USD 320.7 Billion in 2028, Says Brandessence Market Research - Yahoo FinanceJune 27, 2022 | businesswire.comGlancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Its Investigation of NeoGenomics, Inc. (NEO) on Behalf of Investors - Business WireJune 27, 2022 | finance.yahoo.comNeoGenomics (NEO) Surges 6.4%: Is This an Indication of Further Gains?June 26, 2022 | americanbankingnews.comNeoGenomics (NASDAQ:NEO) Rating Increased to Sell at StockNews.comJune 25, 2022 | americanbankingnews.comNeoGenomics (NASDAQ:NEO) Stock Price Up 9.4%June 24, 2022 | globenewswire.comBragar Eagel & Squire, PC Is Investigating Outset - GlobeNewswireJune 24, 2022 | businesswire.comThe Law Offices of Frank R. Cruz Continues Its Investigation of NeoGenomics, Inc. (NEO) on Behalf of Investors - Business WireJune 21, 2022 | finance.yahoo.comNeoGenomics Liquid Biopsy Subsidiary Inivata Announces New Data Demonstrating Clinical Potential of the RaDaR(TM) MRD Test in HR+ HER2- Breast Cancer - Yahoo FinanceJune 21, 2022 | finance.yahoo.comNeoGenomics Liquid Biopsy Subsidiary Inivata Announces New Data Demonstrating Clinical Potential of the RaDaR(TM) MRD Test in HR+ HER2- Breast CancerJune 20, 2022 | finance.yahoo.comNeoGenomics, Inc. (NASDAQ:NEO) insider upped their holding by 31% earlier this yearJune 19, 2022 | americanbankingnews.comNeoGenomics, Inc. (NASDAQ:NEO) Receives Average Recommendation of "Buy" from AnalystsJune 19, 2022 | americanbankingnews.comNeoGenomics (NASDAQ:NEO) Trading 7.9% Higher See More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Testing laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NEO CUSIPN/A CIK1077183 Webwww.neogenomics.com Phone(239) 768-0600Fax239-690-4237Employees2,000Year FoundedN/ACompany Calendar Last Earnings4/27/2022Today7/01/2022Next Earnings (Estimated)8/05/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$20.82 High Stock Price Forecast$30.00 Low Stock Price Forecast$13.00 Forecasted Upside/Downside+148.7%Consensus RatingModerate Buy Rating Score (0-4)2.7 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($0.320010) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8.35 million Net Margins-7.33% Pretax Margin-9.69% Return on Equity-6.62% Return on Assets-3.94% Debt Debt-to-Equity Ratio0.50 Current Ratio7.93 Quick Ratio7.64 Sales & Book Value Annual Sales$484.33 million Price / Sales2.16 Cash Flow$0.16 per share Price / Cash Flow51.21 Book Value$9.00 per share Price / Book0.93Miscellaneous Outstanding Shares124,758,000Free Float123,510,000Market Cap$1.04 billion OptionableOptionable Beta0.87 NeoGenomics Frequently Asked Questions Should I buy or sell NeoGenomics stock right now? 10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last twelve months. There are currently 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" NeoGenomics stock. View analyst ratings for NeoGenomics or view top-rated stocks. What is NeoGenomics' stock price forecast for 2022? 10 analysts have issued twelve-month price targets for NeoGenomics' stock. Their NEO stock forecasts range from $13.00 to $30.00. On average, they anticipate NeoGenomics' share price to reach $20.82 in the next twelve months. This suggests a possible upside of 148.7% from the stock's current price. View analysts' price targets for NeoGenomics or view top-rated stocks among Wall Street analysts. How has NeoGenomics' stock performed in 2022? NeoGenomics' stock was trading at $34.12 on January 1st, 2022. Since then, NEO shares have decreased by 75.5% and is now trading at $8.37. View the best growth stocks for 2022 here. When is NeoGenomics' next earnings date? NeoGenomics is scheduled to release its next quarterly earnings announcement on Friday, August 5th 2022. View our earnings forecast for NeoGenomics. How were NeoGenomics' earnings last quarter? NeoGenomics, Inc. (NASDAQ:NEO) announced its quarterly earnings results on Wednesday, April, 27th. The medical research company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.28) by $0.02. The medical research company had revenue of $117.17 million for the quarter, compared to the consensus estimate of $116.44 million. NeoGenomics had a negative net margin of 7.33% and a negative trailing twelve-month return on equity of 6.62%. NeoGenomics's quarterly revenue was up 1.4% compared to the same quarter last year. During the same period last year, the firm posted ($0.06) EPS. View NeoGenomics' earnings history. What guidance has NeoGenomics issued on next quarter's earnings? NeoGenomics updated its first quarter 2022 earnings guidance on Monday, April, 25th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of -$118 million, compared to the consensus revenue estimate of $119.16 million. Who are NeoGenomics' key executives? NeoGenomics' management team includes the following people: Ms. Lynn A. Tetrault Esq., J.D., Chair of the Board & Interim CEO (Age 59, Pay $97.67k)Mr. George A. Cardoza, Pres & COO of Lab Operations (Age 60, Pay $800.5k) (LinkedIn Profile)Ms. Kathryn B. McKenzie, Chief Sustainability & Risk Officer (Age 38, Pay $793.48k) (LinkedIn Profile)Mr. William Bishop Bonello, Chief Financial Officer (Age 57)Ms. Cynthia J. Dieter, Chief Accounting Officer (Age 47)Mr. John Mooney, Chief Technology OfficerDr. Shashikant Kulkarni Facmg, M.B.A., M.S., Ph.D., Exec. VP of R&D and Chief Scientific OfficerCharlie Eidson, Director of Investor Relations and Corp. Devel.Mr. Hutan Hashemi J.D., Chief Compliance OfficerMr. Marcus B. Silva J.D., M.B.A., Chief Marketing Officer (Age 46) What is Douglas M. VanOort's approval rating as NeoGenomics' CEO? 116 employees have rated NeoGenomics CEO Douglas M. VanOort on Glassdoor.com. Douglas M. VanOort has an approval rating of 98% among NeoGenomics' employees. This puts Douglas M. VanOort in the top 20% of approval ratings compared to other CEOs of publicly-traded companies. Who are some of NeoGenomics' key competitors? Some companies that are related to NeoGenomics include Evotec (EVTCY), Intellia Therapeutics (NTLA), QuidelOrtho (QDEL), Aspen Pharmacare (APNHY), ICU Medical (ICUI), H. Lundbeck A/S (HLUYY), Abcam (ABCZY), Tandem Diabetes Care (TNDM), Mirati Therapeutics (MRTX), Ortho Clinical Diagnostics (OCDX), Cerevel Therapeutics (CERE), Bausch Health Companies (BHC), Denali Therapeutics (DNLI), Ablynx (ABLYF) and Arrowhead Pharmaceuticals (ARWR). View all of NEO's competitors. What other stocks do shareholders of NeoGenomics own? Based on aggregate information from My MarketBeat watchlists, some companies that other NeoGenomics investors own include Marvell Technology (MRVL), NVIDIA (NVDA), Alibaba Group (BABA), Square (SQ), Inseego (INSG), PayPal (PYPL), Micron Technology (MU), Invitae (NVTA), CRISPR Therapeutics (CRSP) and AbbVie (ABBV). What is NeoGenomics' stock symbol? NeoGenomics trades on the NASDAQ under the ticker symbol "NEO." How do I buy shares of NeoGenomics? Shares of NEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is NeoGenomics' stock price today? One share of NEO stock can currently be purchased for approximately $8.37. How much money does NeoGenomics make? NeoGenomics (NASDAQ:NEO) has a market capitalization of $1.04 billion and generates $484.33 million in revenue each year. The medical research company earns $-8.35 million in net income (profit) each year or ($0.320010) on an earnings per share basis. How many employees does NeoGenomics have? NeoGenomics employs 2,000 workers across the globe. How can I contact NeoGenomics? NeoGenomics' mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The official website for NeoGenomics is www.neogenomics.com. The medical research company can be reached via phone at (239) 768-0600, via email at [email protected], or via fax at 239-690-4237. This page (NASDAQ:NEO) was last updated on 7/2/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
